Objective: In chronic atrial fibrillation (cAF) the potassium current I K,ACh develops agonist-independent constitutive activity. We hypothesized that abnormal phosphorylation-dependent regulation underlies the constitutive I K,ACh activity. Methods: We used voltage-clamp technique and biochemical assays to study I K,ACh regulation in atrial appendages from 61 sinus rhythm (SR), 11 paroxysmal AF (pAF), and 33 cAF patients. Results: Compared to SR basal current was higher in cAF only, whereas the muscarinic receptor (2 μmol/L carbachol)-activated I K,ACh was smaller in pAF and cAF. In pAF the selective I K,ACh blocker tertiapin abolished the muscarinic receptor-activated I K,ACh but excluded agonist-independent constitutive I K,ACh activity. Blockade of type-2A phosphatase and the subsequent shift to increased muscarinic receptor phosphorylation (and inactivation) reduced muscarinic receptor-activated I K,ACh in SR but not in cAF, pointing to an impaired function of Gprotein-coupled receptor kinase. Using subtype-selective kinase inhibitors we found that in SR the muscarinic receptor-activated I K,ACh requires phosphorylation by protein kinase G (PKG), protein kinase C (PKC), and calmodulin-dependent protein kinase II (CaMKII), but not by protein kinase A (PKA). In cAF, constitutive I K,ACh activity results from abnormal channel phosphorylation by PKC but not by PKG or CaMKII, whereas the additional muscarinic receptor-mediated I K,ACh activation occurs apparently without involvement of these kinases. In cAF, the higher protein level of PKCε but not PKCα, PKCβ 1 or PKCδ is likely to contribute to the constitutive I K,ACh activity. Conclusions: The occurrence of constitutive I K,ACh activity in cAF results from abnormal PKC function, whereas the muscarinic receptormediated I K,ACh activation does not require the contribution of PKG, PKC or CaMKII. Selective drug targeting of constitutively active I K,ACh channels may be suitable to reduce the ability of AF to become sustained.
Introduction
Atrial fibrillation (AF) is the most frequent arrhythmia in the clinical setting. It is accepted that electrical and structural remodeling including abbreviated action potentials and refractoriness, hypertrophy and fibrosis promote the existence of reentry circuits and the progression of AF [1] . Studies in animal models and in patients with chronic AF (cAF) suggest that the G-protein-gated potassium current I K,ACh plays a crucial role in atrial arrhythmogenesis [2] [3] [4] [5] [6] .
We have shown that the background inward rectifier potassium current I K1 is higher in cAF and was associated Cardiovascular Research 74 (2007) 426 -437 www.elsevier.com/locate/cardiores with smaller muscarinic receptor-mediated I K,ACh activation [3] [4] [5] . Interestingly cAF patients exhibit agonistindependent constitutive I K,ACh activity that contributes to the enhanced basal inward rectifier current [5] . In dogs a corresponding constitutively active I K,ACh -like current exists which is up-regulated in response to atrial tachypacing [6, 7] . Blockade of this current by the selective IK, ACh-blocker tertiapin resulted in action potential prolongation and suppression of inducible AF episodes [6] . Thus, identifying the culprit abnormalities in I K,ACh regulation may lead to novel therapeutic targets for AF prevention and therapy. The molecular basis of constitutively active I K,ACh in cAF is unknown. At the single channel level, agonist-independent I K,ACh activity in cAF results from higher channel open probability without changes in amplitudes and open times. Earlier studies suggest that agonist-independent activation of I K,ACh requires ATP [8] [9] [10] . Thus modified phosphorylation of I K,ACh and regulatory proteins may contribute to constitutively active I K,ACh in cAF. The I K,ACh channel forms a macromolecular complex, allowing for local I K,ACh regulation. The GIRK1 channel complex may comprise the catalytic subunits of protein kinases A (PKA) and C (PKC), the calmodulin-regulated protein kinase II (CaMKII), and the type-1 and type-2A protein phosphatases PP1 and PP2A [11] . The kinase/phosphatase signaling in the cellular microdomains of cAF patients is inhomogeneous resulting in increased, decreased or normal phosphorylation levels of proteins despite enhanced total PP1 and PP2A activity [12] [13] [14] . Thus, the quantitative and qualitative composition of the macromolecular channel complex may change during cAF resulting in abnormal phosphorylation-dependent I K,ACh regulation.
The present study tested the hypothesis that alterations in phosphorylation-dependent channel regulation may contribute to constitutive I K,ACh activity in cAF.
Materials and methods

Human samples
The study was approved by the local ethics committee of the university (No: EK790799) and each patient gave written informed consent. The investigation conforms with the principles outlined in the Declaration of Helsinki (Cardiovascular Research 1997;35:2-4).
Right atrial appendages were obtained from 61 patients with SR, 11 patients with paroxysmal AF (pAF) and 33 patients with cAF (cAF N 6 months, Table 1 and supplementary data).
Electrophysiological recordings
Atrial myocytes were isolated using our previous protocol [15] and were suspended in storage solution (in mmol/L: KCl 20, KH 2 PO 4 10, glucose 10, K-glutamate 70, β-hydroxybutyrate 10, taurine 10, EGTA 10, albumin 1, pH = 7.4). Membrane currents were measured with voltageclamp technique. ISO-2 software (MFK) was used for data acquisition and analysis.
Borosilicate glass microelectrodes had tip resistances of 2-5 MΩ when filled with pipette solution (in mmol/L: Kaspartate 80, NaCl 8, KCl 40, Mg-ATP 5, EGTA 2, GTPTris 0.1, HEPES 10, pH = 7.4). Myocytes were superfused with a solution containing (in mmol/L): NaCl 120, KCl 20, MgCl 2 1, CaCl 2 2, glucose 10, HEPES 10, pH = 7.4 at 22-24°C. Seal resistances were 4-8 GΩ. Series resistance and cell capacitance were compensated. Agonist-independent basal current was measured by applying a ramp pulse from − 100 to +40 mV (Fig. 1A) . Agonist-inducible I K,ACh was stimulated with carbachol (CCh, 2 μmol/L) in the absence and presence of selective inhibitors of protein kinase G (PKG; KT5823, 1 μmol/L), PKC (bisindolylmaleimide-I [BIM-I] and its inactive form bisindolylmaleimide-V [BIM-V], 0.1 μmol/L each), CaMKII (KN-93 and its inactive form KN-92, 0.2 μmol/L each), protein kinase A (PKA; KT5720, 1 μmol/L), PP1/PP2A (okadaic acid, 1 μmol/L) and type-2B protein phosphatase calcineurin (PP2B; cyclosporin A, 10 μmol/L). All drugs were from Calbiochem. 
Ba
2+ (1 mmol/L) was applied in each myocyte and the currents were analyzed after subtraction of the resulting leak current. The myocytes were superfused with Tyrode's solution, and the drugs were applied via an additional rapid solution exchange system (ALA Scientific Instruments, Long Island, NY, USA). To control for myocyte-size variability, the currents are expressed as densities (pA/pF).
Western blot analysis
Protein levels of calsequestrin (1:2500; Dianova), PKCα (1:1000), PKCβ 1 (1:250), PKCδ (1:250), and PKCε (1:500; all Santa Cruz) were quantified in atrial homogenates by Western blotting as described [16] . Immunological signals were visualized with anti-IgG-horseradish-peroxidase and enhanced chemifluorescence (Amersham) and quantified using Quantity One software (BioRad).
Molecular analysis of the Gβ 3 gene
Direct activation of I K,ACh is mediated by G-protein βγ-subunits. The G-protein β 3 subunit gene (GNB3) contains a C825T-polymorphism, whereby homozygous 825T-allele carriers exhibit larger basal inward rectifier K + current possibly due to enhanced signal transduction. To exclude confounding by homozygous 825T-allele carriers, all patients were genotyped [15] . The patient sample includes homozygous and heterozygous C825-allele carriers only.
Statistical analysis
One-way ANOVAs were applied to determine the sources of K + -current and protein variation (SPSS version 12.0). Independent variables were rhythm status, selected clinical variables and medication (Table 1 and supplementary data). To test for interactions between rhythm status and clinical variables or medication, interaction terms were included in separate two-way ANOVA. Differences between group means for continuous data were compared by unpaired Student's t-test or by one-way ANOVA and Bonferroni multiple comparisons procedure. Frequency data were analyzed with χ 2 statistics. Data are means ± SEM. P b 0.05 was considered statistically significant.
Results
Significant differences between the groups were found for gender, age, coronary artery disease, valvular heart disease, hyperlipidemia and left atrial diameter. cAF patients more often received digitalis but less frequently lipid-lowering drugs. Diuretics were more often prescribed in pAF and cAF than SR (Table 1 ). With one-way ANOVAs, AF was the only predictor of current densities and protein levels (not shown).
Basal current and CCh-activated I K,ACh
Cell capacitances averaged 99.6 ± 3.1 pF (n = 108/48; myocytes/patients) for SR, 80.9 ± 6.5 pF (n = 23/11) for pAF and 109.3 ± 5.3 pF (n = 48/20) for cAF myocytes (P = N.S.). Typical current traces and current amplitudes at − 100 mV in the time course of an experiment are shown in Fig. 1A ,B. Basal currents in SR and pAF were similar (−12.8 ± 0.7 pA/ pF, n =108/48 vs. −14.1 ± 1.5 pA/pF, n = 23/11), but smaller than in cAF (−20.7 ± 1.2 pA/pF, n =48/20; P b 0.05; Fig. 1C ) confirming previous results [3] [4] [5] 17, 18] . The smaller basal currents in SR and pAF are in accordance with the resting membrane potential (RMP) being less negative in SR and pAF than in cAF (−18.8 ± 0.9 mV, n = 86/48 and −15.6 ±1.6 mV, n = 12/4 vs. −23.0 ± 1.4 mV, n = 48/20; P b 0.05; Fig. 1D ) [3, 4, 17] .
Application of CCh resulted in rapid initial increase ("Peak") of I K,ACh followed by a decrease to a quasi steadystate level ("QSS") despite continuous presence of CCh ("desensitisation"; 1D ). With two-way ANOVA, test of interaction effects between coronary artery disease, valvular heart disease, hyperlipidemia, digitalis, diuretics, lipid-lowering drugs, gender, age or left atrial diameter and I K,ACh showed no significant interaction (not shown).
Effects of tertiapin on basal current and CCh-activated I K,ACh in pAF patients
In experiments with selective inhibitors, I K,ACh was stimulated twice (S1, S2) with 4 min CCh-free period in between. S1 served as internal control, S2 was measured in the presence of inhibitors [5] . Under control conditions I K,ACh was smaller during S2 than S1 suggesting incomplete recovery from desensitisation, but the degrees of I K,ACh desensitisation were similar between the groups ( Fig. 2A) .
In pAF, the selective I K,ACh channel blocker tertiapin (0.1-100 nM) during S2 reduced the S2/S1 ratio in a concentration-dependent manner without an effect on basal current (Fig. 2B ) excluding constitutive I K,ACh activity.
Regulation of basal current and CCh-activated I K,ACh by protein phosphatases
Regulation of I K,ACh through phosphorylation is a dynamic process that reflects the actual balance between kinase and phosphatase activities at the various sites of signal transduction (Fig. 3) . Upon addition of CCh during S1, direct binding of liberated Gβγ-subunits to GIRK1/ GIRK4 causes rapid activation of I K,ACh (1) [10] followed by desensitisation, the fast phase of which (green) is associated with channel dephosphorylation (2) [19, 20] , whereas the intermediate phase (blue) involves progressive receptor phosphorylation by a G-protein-coupled receptor kinase (GRK) which uncouples the receptor from the Gprotein (3) [21] . During the CCh-free period (4) channel phosphorylation and receptor dephosphorylation recover only incompletely leading to a smaller CCh-activated I K,ACh during S2 [5] . Thus, phosphorylation of muscarinic receptors or I K,ACh channels modulates I K,ACh in a reciprocal manner, with receptor phosphorylation decreasing and channel phosphorylation increasing current amplitude.
Since total PP1 and PP2A activity is higher in cAF than in SR [13, 14] we investigated the contribution of phosphatases to the regulation of I K1 , constitutively active and CChactivated I K,ACh channels. Selective phosphatase inhibitors were applied 3 min before and during S2 (Fig. 4A) . In SR, basal current was affected neither by the PP1/PP2A-inhibitor okadaic acid (1 μmol/L) nor by the calcineurin inhibitor cyclosporin A (10 μmol/L; Fig. 4A,B) and there was no change in RMP with either inhibitor (Fig. 4C) . In contrast, inhibition of PP1 and PP2A led to a small but significant reduction of basal current in cAF (Fig. 4A,B) , which was associated with a significant change of RMP leading to less negative potentials (Fig. 4C) .
Discriminating the contribution of phosphatases to I K,ACh is impeded by concomitant modulation of receptor phosphorylation (Fig. 3) . PP2A (but not PP1 and calcineurin) is a component of the M 2 -receptor complex [11] and PP2A inhibition is expected to shift the balance in favor of receptor phosphorylation by GRK resulting in reduced I K,ACh activation (Fig. 3) [21] . In the presence of okadaic acid, CCh-activated Peak-and QSS-I K,ACh were ∼35% lower in SR, whereas cyclosporin A was without effect (Fig. 4D) . In cAF, however, okadaic acid did not affect CCh-activated I K,ACh suggesting potentially impaired function of GRK (Fig. 4D) . The CCh-induced changes in RMP exhibited large inter-and intra-patient variability (Fig. 1D) . Therefore, in analogy to the S2/S1 analysis of CCh-activated I K,ACh , the corresponding effects of CCh on RMP were expressed as the ratio of the CCh-induced changes in RMP during S1 and S2, i.e. the CCh-sensitive change in RMP (ΔRMP) during S2 is divided by the corresponding value during S1 (ΔRMP(S2) / ΔRMP(S1)). In SR, the okadaic acid-associated decreases of CCh-activated I K,ACh resulted in corresponding changes in RMP (Fig. 4E) .
Regulation of basal current and CCh-activated I K,ACh by protein kinases
In SR, the PKG-inhibitor KT5823 (1 μmol/L) reduced basal current by 3.9 ± 1.1 pA/pF (n = 9/4), though without significant changes in RMP (Fig. 5A-C ). Since basal current in SR consists of I K1 only [5] , our results suggest that I K1 requires channel phosphorylation by PKG. The PKC-inhibitor BIM-I (0.1 μmol/L), the CaMKII-inhibitor KN-93 (0.2 μmol/L) and the PKA-inhibitor KT5720 (1 μmol/L) had no effect on basal current in SR (Fig.  5A,B) . Accordingly, RMP remained unchanged (Fig. 5C ). Basal current in cAF involves I K1 and constitutively active I K,ACh [5] . Thus any change in basal current could result from impaired regulation of either channel. KT5823 decreased basal current in cAF in the same order of magnitude as in SR confirming the positive regulation of I K1 by PKG (Fig. 6A,B) . KN-93 and its inactive analog had no effect on basal current or RMP. BIM-I, but not its negative analog, reduced basal current by 3.4 ± 0.8 pA/pF (n = 7/3) and changed RMP to more positive potentials (Fig. 6A-C) .
Lack of contribution of CaMKII, PKC, PKG and PKA to muscarinic receptor phosphorylation allows to investigate the contribution of these kinases to I K,ACh regulation without confounding effects on muscarinic receptor function (Fig. 3) [11, 22] . In SR, KT5823, BIM-I and KN-93 reduced Peak-but not QSS-I K,ACh . The inactive analogs were without effect (Fig. 7A) . The kinase inhibitor-associated decreases of Peak-I K,ACh were paralleled by corresponding changes in RMP (Fig. 7B) . Signal transduction via muscarinic receptors does not involve activation of PKA [23] and accordingly KT5720 did not affect CCh-activated I K,ACh (Fig. 7A) . In cAF, however, the kinase inhibitors did not modulate CCh-activated I K,ACh , and correspondingly, there was no change in RMP (Fig. 7A,B) .
Protein levels of PKC isoforms
Levels of proteins were normalized to the tissue amount of calsequestrin, which was similar in SR and cAF (Fig. 8) . The protein level of PKCε, but not PKCα, PKCβ 1 or PKCδ, was ∼40% higher in cAF than in SR (Fig. 8) . Compared to SR the cAF patients had larger left atria and more frequently valvular heart disease but comparable other clinical parameters and medications (Supplementary data). There was no significant interaction effect between left atrial diameter or presence of valvular heart disease and cAF on PKCε (not shown). Thus, abnormal PKC activity and specifically PKCε is likely to contribute to constitutive I K,ACh activity.
Discussion
Evidence for abnormal phosphorylation-dependent regulation of constitutively active and CCh-activated I K,ACh is provided by several observations: (i) basal current in SR, consisting of I K1 only, was not affected by inhibition of protein phosphatases, PKC or CaMKII, whereas in cAF it decreased after inhibition of PKC (but not of CaMKII). (ii) The increased protein abundance of PKCε is likely to contribute to the promotion of constitutive I K,ACh activity by PKC; (iii) selective inhibition of PP1 and PP2A reduced CCh-activated Peak-and QSS-I K,ACh in SR but not in cAF suggesting impaired GRK function; (iv) the selective block of PKG, PKC or CaMKII decreased the CCh-activated Peak-I K,ACh without affecting QSS-I K,ACh only in SR but not in cAF. Our results indicate that the occurrence of constitutive I K,ACh activity in cAF may result from abnormal I K,ACh channel phosphorylation by PKC, whereas the additional muscarinic receptor-mediated I K,ACh activation apparently occurs without significant contribution of PKG, PKC or CaMKII. 
Comparison with previous studies
We have recently shown that I K,ACh develops constitutive activity in cAF patients [5] . In dogs with pacing-induced tachycardia, atria and pulmonary veins develop a similar I K,ACh -like component of basal current [6, 7] . Blockade of these channels with the selective blocker tertiapin prevents induction of AF episodes [6] suggesting that I K,ACh is a major contributor to initiation and perpetuation of AF. However, pAF patients did not possess a tertiapin-sensitive component of basal current indicating that constitutive I K,ACh activity is a hallmark of cAF, but not of pAF, and thus most likely a consequence rather than a cause of the arrhythmia.
Consistent with ∼ 40% reduction in protein levels of the GIRK1 subunit [24] the muscarinic receptor-activated I K,ACh was ∼ 40% smaller in pAF than in SR. The 10-fold lower potency of tertiapin in pAF (present study) than in cAF [5] suggests also impaired channel regulation. Thus modulation of atrial function by vagal excitation appears limited in pAF patients.
The molecular basis of constitutively active I K,ACh is incompletely understood. In cAF open probability of agonist-independent I K,ACh is higher than in SR without concomitant alterations of other current properties [5] . Lack of effect of the muscarinic receptor blocker atropine demonstrates that constitutive I K,ACh activity is an agonistindependent process [5, 7] . Increased receptor-independent dissociation of Gα-and Gβγ-subunits appears an unlike mechanism because neither pertussis toxin nor absence of GTP affected the I K,ACh -like component of basal current in dogs [7] . These findings point to a modified regulation within the macromolecular I K,ACh complex which contains the catalytic subunits of PKA, PKC, and CaMKII, and PP1 and PP2A [10, 11] . Thus, the quantitative and/or qualitative composition of this complex may change in cAF leading to abnormal phosphorylation-dependent I K,ACh regulation.
Activation of I K,ACh requires ATP which may modulate the channel through several mechanisms: (i) transphosphorylation between adenosine-and guanosine-nucleosides via nucleoside diphosphate kinase (NDPK) [8] ; (ii) generation of phosphatidylinositol-4,5-bisphosphate (PIP2) via hydrolysis of ATP [25] and (iii) direct phosphorylation of the channels and/or their regulators by protein kinases [10, 19] . Recent work, however, challenged the NDPK hypothesis as explanation for agonist-independent channel activation [26] . Although the levels of high-energy phosphates remain stable in cAF [27] , high membrane levels of PIP2 underlying the constitutive I K,ACh activity cannot be excluded. The phosphorylation state of muscarinic receptors and I K,ACh channels is dynamically regulated by different kinase and phosphatase subtypes. Consistent with results in animals [19] inhibition of PP1/PP2A reduced CCh-activated I K,ACh in SR suggesting that the shift in the kinase/phosphatase balance to higher channel phosphorylation cannot compensate the stronger muscarinic receptor phosphorylation thereby limiting the activation of I K,ACh (Fig. 3) . In contrast PP1/PP2A inhibition was without effect on CCh-activated I K,ACh in cAF indicating abnormal function of GRK.
The regulation of muscarinic receptor function does not involve phosphorylation by CaMKII, PKC and PKA (Fig. 3) [22] . This allows to investigate the contribution of these kinases to channel regulation without confounding effects on muscarinic receptor function. The GIRK1 and GIRK4 channel subunits possess phosphorylation sites for PKA, PKC, and CAMKII and possibly PKG [10, 11] and regulation of CCh-activated I K,ACh was modulated by PKC, CaMKII and PKG but not by PKA. In SR, the kinase inhibitors reduced CCh-activated Peak-I K,ACh without an effect on QSS-I K,ACh . Since Peak-I K,ACh reflects the direct binding of the Gβγ-subunits to the channel and the strength of this binding depends on the actual degree of channel phosphorylation (Fig. 3) [10] , PKG-, PKC-and CaMKIImediated channel phosphorylation may stabilize the binding of Gβγ-subunits to the channel increasing I K,ACh . In contrast, the kinase inhibitors were without effect on CChactivated I K,ACh in cAF. This was unexpected, because the protein levels of CaMKIIδ and PKCε are higher in cAF than in SR [28] . Also, we consistently found that the activity of PP1 and PP2A is higher in cAF than in SR and does not translate into homogeneous changes of protein phosphorylation [13, 14] . Thus the lack of contribution of these kinases to CCh-activated I K,ACh in cAF may result from a stronger channel dephosphorylation (Fig. 3) . Alternatively, the channels may be hyperphosphorylated due to abnormal control of kinase/phosphatase signaling in the macromolecular complex [14] and inhibition of a single kinase may not reduce the channel's phosphorylation state below the threshold required to impair CCh-activated I K,ACh . Further work is needed to verify these hypotheses.
Inhibition of PP1/PP2A and calcineurin, and several protein kinases (PKA, PKC and CaMKII) did not affect basal current in SR. Phosphorylation of I K1 channels by protein kinases results in current inhibition [29, 30] and the PKG-inhibitor KT5823 reduced basal current in SR and cAF. This inhibition, however, was of similar magnitude in both groups suggesting potential block of I K1 channels. In the kidney, PKG increases the amplitude of inward rectifier K + current [31] pointing to the involvement of PKG in I K1 regulation. Further studies are required to clarify the role of PKG in I K1 regulation.
The CaMKII-inhibitor KN-93 had no effect on basal current in cAF rendering the contribution of CaMKII to either I K1 or constitutively active I K,ACh channels unlikely. Surprisingly, inhibition of PKC with BIM-I reduced basal current in cAF by ∼3.5 pA/pF. In human atria activation of Gαq-coupled receptors results in translocation of PKCδ and PKCε (but not PKCα or PKCβ) to the membrane [32] , and the protein levels of PKCε are higher in cAF than in SR. Thus, the inhibition of basal current by BIM-I in cAF may result from abnormal contribution of PKCε. Since BIM-I was not effective on basal current in SR (only I K1 present) and activation of PKC inhibits human I K1 [33] , the BIM-I-associated decrease in basal current in cAF must involve impaired regulation of constitutively active I K,ACh . Thus while development of constitutively active I K,ACh in cAF requires abnormal channel phosphorylation by PKC, the additional muscarinic receptor-mediated I K,ACh activation apparently does not need the contribution of PKG, PKC or CaMKII.
Study limitations
Our results are not consistent with data from expression systems and neonatal myocytes where the increase in PKC activity inhibits I K,ACh [11, 34] . The reason for this inconsistent observation is unknown, though artificial systems lack important endogenous regulators, and the composition of the I K,ACh channel differs between neonatal and adult myocytes [35] . The predominant subunit in neonatal rat myocytes is GIRK4 [35] , whereas in diseased human atria GIRK1 predominates (unpublished data, 2002). Thus, species differences and the concomitant cardiac disease and/or patients' medication could also contribute to the discrepant findings.
We studied the contribution of serine/threonine kinases only. However, mitogen-activated protein kinases (MAPKs) may also contribute to the regulation of I K,ACh . PKCε is known to activate ERK1/2 [36, 37] and may stimulate JNK and p38 [37] through an indirect increase of PKCδ [38] . Thus, we cannot exclude that MAPKs regulate I K,ACh and that the effects of PKC on constitutively active I K,ACh are mediated by stimulation of MAPKs. An inactive analog of KT5823 was not available to us. Thus, our results with this drug might be confounded by non-specific effects on I K1 .
Clinical implications
In vivo, constitutively active I K,ACh is expected to shorten action potential duration, to enhance atrial vulnerability to tachyarrhythmia and to sustain AF [1] . Here we demonstrate that the molecular basis of constitutively active I K,ACh in cAF may involve abnormal phosphorylation-dependent regulation by PKC. To the best of our knowledge this is the first demonstration of increased PKCε expression in cAF. This may contribute to contractile dysfunction [39, 40] , hypertrophy and fibrosis, however, proof of these hypotheses warrants further investigations.
